“probably the most meaningful part of that will show up in the early '25 to be honest, as that new form ramps and details on that rollout will be coming in the coming weeks.”

In context

“is inventory restock that you talked about today suggests maybe more of a meaningful step-up. So just can you quantify for us where you are in the ramp in RTP? Thank you. Joe Fletcher : Yes, sure. I think, Dave, do you want to hop in and... Dave Ricks: Yes, I can just can -- So I think what we're saying today is just reiterating the 1.5 is sort of like a floor on how we think about second half volume. I would say the vials are part of that. But given the -- we have about 20 weeks left in the year. So, there's a limit to how much of that will ship anyway. But they certainly open up a node of the most constrained part of the supply chain, which is still finish in the final container closure and it uses different lines obviously, then syringes or cartridges. So, it just adds to our capacity, probably the most meaningful part of that will show up in the early '25 to be honest, as that new form ramps and details on that rollout will be coming in the coming weeks. As it relates to RTP, I wouldn't read through that the Q2 step-up in volume we shipped was primarily to RTP. That site is on track, and we are steadily escalating production per our goals. I also mentioned Concord is doing well against its time schedule, and we expect product out of that site end of this year, early next year. But rather, maybe performance out of the totality of the network that allowed us to recover wholesaler inventory levels in Q2 and now come off the FDA shortage list. It's more just overall performance across many, many nodes of our supply network. Operator: The next question will be from Chris Schott from JPMorgan. Chris your line is live. Chris Schott: And congrats all the progress. There seems to be a broader debate on the role emerging earlier-stage competition i”